<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sarandakou, Angeliki</style></author><author><style face="normal" font="default" size="100%">Phocas, Iphigenia</style></author><author><style face="normal" font="default" size="100%">Sikiotis, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Rizos, Demetrios</style></author><author><style face="normal" font="default" size="100%">Botsis, Demetrios</style></author><author><style face="normal" font="default" size="100%">Kalambokis, Dimitrios</style></author><author><style face="normal" font="default" size="100%">Trakakis, Eftihios</style></author><author><style face="normal" font="default" size="100%">Chryssikopoulos, Athanassios</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cytokines in gynecological cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervical adenocarcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervical squamous cell carcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Endometrial carcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">sIL-2R</style></keyword><keyword><style  face="normal" font="default" size="100%">TNF</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1997</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1997///</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">3835 - 3839</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: Cytokines are considered as part of host defence to infection or injury. Material and Methods: Pretreatment values of TNF and sIL-2R were measured in 132 women with a) ovarian carcinoma (n = 25), b) breast cancer (n = 20), c) endometrial cancer (n = 15), d) cervical squamous cell carcinoma (n = 19), e) cervical adenocarcinoma (n = 11) and f) benign gynecological diseases (n = 42) in order to evaluate whether these cytokines could be useful in the discrimination of malignant from benign gynecological diseases. Results: Both TNF and sIL-2R were significantly higher in all cancer groups together (mean ± SD:30 ± 11 pg/mL and 1293 ± 465 U/mL respectively), than those in the benign group (16.0 ± 6 pg/mL and 626 ± 233 U/mL, respectively; p &lt; 0.001), while no significant differences were found for TNF and sIL-2R values in the five cancer groups. Significantly higher cytokine values were measured in the advanced stage diseases (33 ± 11 pg/mL and 1705 ± 192 U/mL), than those in the limited cancer (26 ± 12 pg/mL, p &lt; 0.05 and 916 (521 U/mL, p &lt; 0.001). Conclusions: Our results suggest that, cytokines may be useful in the discrimination of malignant from benign gynecological diseases and in monitoring tumor activity in patients early in the malignancy process.</style></abstract><issue><style face="normal" font="default" size="100%">5 B</style></issue></record></records></xml>